Logo do repositório
 
Publicação

Effects of pituitary adenylate cyclase activating peptide (PACAP) and related peptides on human retinoblastoma Y79 cells

datacite.subject.fosCiências da Saúdept_PT
dc.contributor.advisorSilva, Maria João
dc.contributor.advisorZawilska, Jolanta
dc.contributor.advisorWojcieszak, Jakub
dc.contributor.authorHonório, José Miguel Santos da Fonseca Beja
dc.date.accessioned2017-11-03T15:42:53Z
dc.date.available2017-11-03T15:42:53Z
dc.date.issued2014
dc.date.submitted2013
dc.descriptionTrabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2014pt_PT
dc.description.abstractRetinoblastoma is an aggressive neuroblastic tumour and, although rare, it is the most common primary intraocular malignancy of infancy and childhood. If untreated, retinoblastoma will grow and produce seeding in the eye, leading to retinal detachment, necrosis and invasion of the orbit, optic nerve, and central nervous system. Numerous clinical data indicate that retinoblastoma may be fatal. The Y79 line is the most prominent retinoblastoma cell line. It has been demonstrated that PACAP38, a neuropeptide belonging to the secretin superfamily of peptides exerts cytotoxic activity against Y79 retinoblastoma cells. In this work effects of PACAP38 and PACAP6-38 (an antagonist of mammalian PAC1 receptors) on survival of Y79 cells were compared to the action of other peptides from the secretin family, namely GLP7-36, GLP7-37 and its stable analogue, exendin-4. MTT cell viability assay and BrdU cell proliferation assay were performed to assess cytotoxic and/or antiproliferative activity for the peptides and their combinations. In some experiments the action of peptides was evaluated in the presence of sitagliptin, an inhibitor of DPP4. Moreover, for the first time, DPP4 expression at mRNA level in Y79 retinoblastoma cells was demonstrated.pt_PT
dc.description.sponsorshipFaculty of Pharmacy of the Medical University of Łódź, Department of Pharmaceutical Chemistry and Drug Analysispt_PT
dc.identifier.urihttp://hdl.handle.net/10451/29596
dc.language.isoengpt_PT
dc.subjectRetinoblastomapt_PT
dc.subjectPACAPpt_PT
dc.subjectGLPpt_PT
dc.subjectExendinpt_PT
dc.subjectSitagliptinpt_PT
dc.subjectDPP4pt_PT
dc.subjectMTT assaypt_PT
dc.subjectBrdU assaypt_PT
dc.subjectPCRpt_PT
dc.titleEffects of pituitary adenylate cyclase activating peptide (PACAP) and related peptides on human retinoblastoma Y79 cellspt_PT
dc.typemaster thesis
dspace.entity.typePublication
rcaap.rightsrestrictedAccesspt_PT
rcaap.typemasterThesispt_PT
thesis.degree.nameMestrado Integrado em Ciências Farmacêuticaspt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
MICF_Jose_Honorio.pdf
Tamanho:
1.02 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição: